Chris is passionate about technologies enabling precision medicine.
He focuses on healthcare investments at OCV and Co-led investments including Praxis Precision Medicines, Finch Therapeutics, and Precision Biosciences. Prior to OCV Dr. Bostick completed postdoctoral work at the Institute for Genomic Medicine at Columbia University where he studied precision medicine-based approaches for treating genetic neurological disorders. Prior to that he did research for his Ph.D. in drug metabolism, bioelectronics/biosensors, and nanotechnology. Dr. Bostick holds a B.S. in Biology from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University.
Chris serves as a Board Member for the following portfolio companies:
- Rad AI
- Ossio (Observer)
- TORL (Observer)